NFKB1 and diffuse large B-cell lymphoma: As TAK1 appears to play an integral role in mediating constitutive MYD88L265P activation of NF-κB in both WM and DLBCL, it is not surprising that use of a TAK1-specific inhibitor significantly decreased cell proliferation and viability.